Rigel Pharmaceuticals Inc
RIGL22.320USD
+0.410+1.87%
Market hours （ET）Quotes delayed by 15 min
398.79MMarket Cap
10.73P/E TTM
More Details of Rigel Pharmaceuticals Inc Company
Rigel Pharmaceuticals, Inc. is a biotechnology company. The Company is engaged in developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer. It is focused on products that address signaling pathways that are critical to disease mechanisms. Its first product is TAVALISSE (fostamatinib disodium hexahydrate) tablets, the approved oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment. Its second product is REZLIDHIA (olutasidenib) capsules for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test. Its GAVRETO (pralsetinib) product is a once daily, small molecule, oral, kinase inhibitor of wild type rearranged during transfection (RET) and oncogenic RET fusions.
Company Info
Ticker SymbolRIGL
Company nameRigel Pharmaceuticals Inc
IPO dateNov 29, 2000
CEOMr. Raul R. Rodriguez
Number of employees162
Security typeOrdinary Share
Fiscal year-endNov 29
Address- -
City- -
Stock exchangeNASDAQ Global Select Consolidated
Country- -
Postal code- -
Phone- -
Website- -
Ticker SymbolRIGL
IPO dateNov 29, 2000
CEOMr. Raul R. Rodriguez
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. Raul R. Rodriguez
Mr. Raul R. Rodriguez
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
239.45K
-3.76%
Mr. Dean L. Schorno, CPA
Mr. Dean L. Schorno, CPA
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
57.23K
-6.18%
Mr. David A. Santos
Mr. David A. Santos
Executive Vice President, Chief Commercial Officer
Executive Vice President, Chief Commercial Officer
51.70K
-7.05%
Dr. Lisa Rojkjaer, M.D.
Dr. Lisa Rojkjaer, M.D.
Executive Vice President, Chief Medical Officer
Executive Vice President, Chief Medical Officer
19.72K
--
Dr. Walter H. Moos, Ph.D.
Dr. Walter H. Moos, Ph.D.
Independent Director
Independent Director
12.72K
+24.46%
Ms. Jane Wasman, J.D.
Ms. Jane Wasman, J.D.
Independent Director
Independent Director
12.50K
+25.00%
Ms. Kamil Ali-Jackson, Esq., J.D.
Ms. Kamil Ali-Jackson, Esq., J.D.
Independent Director
Independent Director
9.38K
+36.36%
Mr. Gregg A. Lapointe, CPA
Mr. Gregg A. Lapointe, CPA
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Alison L. Hannah, M.D.
Dr. Alison L. Hannah, M.D.
Independent Director
Independent Director
--
--
Mr. Raymond J. Furey
Mr. Raymond J. Furey
Executive Vice President, Chief Compliance Officer, General Counsel, Corporate Secretary
Executive Vice President, Chief Compliance Officer, General Counsel, Corporate Secretary
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Raul R. Rodriguez
Mr. Raul R. Rodriguez
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
239.45K
-3.76%
Mr. Dean L. Schorno, CPA
Mr. Dean L. Schorno, CPA
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
57.23K
-6.18%
Mr. David A. Santos
Mr. David A. Santos
Executive Vice President, Chief Commercial Officer
Executive Vice President, Chief Commercial Officer
51.70K
-7.05%
Dr. Lisa Rojkjaer, M.D.
Dr. Lisa Rojkjaer, M.D.
Executive Vice President, Chief Medical Officer
Executive Vice President, Chief Medical Officer
19.72K
--
Dr. Walter H. Moos, Ph.D.
Dr. Walter H. Moos, Ph.D.
Independent Director
Independent Director
12.72K
+24.46%
Ms. Jane Wasman, J.D.
Ms. Jane Wasman, J.D.
Independent Director
Independent Director
12.50K
+25.00%
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Sat, May 17
Updated: Sat, May 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Armistice Capital LLC
8.48%
Morgan Stanley & Co. LLC
8.28%
BlackRock Institutional Trust Company, N.A.
8.23%
Soleus Capital Management, L.P.
6.33%
The Vanguard Group, Inc.
5.75%
Other
62.92%
Shareholders
Shareholders
Proportion
Armistice Capital LLC
8.48%
Morgan Stanley & Co. LLC
8.28%
BlackRock Institutional Trust Company, N.A.
8.23%
Soleus Capital Management, L.P.
6.33%
The Vanguard Group, Inc.
5.75%
Other
62.92%
Shareholder Types
Shareholders
Proportion
Investment Advisor
28.57%
Investment Advisor/Hedge Fund
20.61%
Hedge Fund
18.26%
Research Firm
9.88%
Individual Investor
2.66%
Pension Fund
0.83%
Sovereign Wealth Fund
0.72%
Bank and Trust
0.14%
Venture Capital
0.09%
Other
18.22%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
289
14.62M
81.83%
+655.24K
2025Q1
295
14.90M
83.36%
+888.64K
2024Q4
281
12.77M
72.51%
-849.60K
2024Q3
291
12.41M
70.53%
-421.54K
2024Q2
303
10.88M
61.98%
-2.99M
2024Q1
319
11.57M
65.99%
-3.84M
2023Q4
326
11.03M
63.24%
-4.70M
2023Q3
343
11.50M
66.01%
-5.45M
2023Q2
356
11.96M
68.88%
-4.98M
2023Q1
359
12.15M
69.98%
-5.32M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Armistice Capital LLC
1.52M
8.48%
+364.00K
+31.60%
Mar 31, 2025
Morgan Stanley & Co. LLC
1.48M
8.28%
-54.14K
-3.53%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
1.47M
8.23%
-33.13K
-2.20%
Mar 31, 2025
Soleus Capital Management, L.P.
1.13M
6.33%
--
--
Mar 31, 2025
The Vanguard Group, Inc.
1.03M
5.75%
+15.14K
+1.49%
Mar 31, 2025
Capitolis Liquid Global Markets LLC
693.10K
3.88%
+693.10K
--
Mar 31, 2025
State Street Global Advisors (US)
637.03K
3.56%
+256.52K
+67.41%
Mar 31, 2025
Acadian Asset Management LLC
565.04K
3.16%
+188.68K
+50.13%
Mar 31, 2025
Geode Capital Management, L.L.C.
411.17K
2.3%
+9.12K
+2.27%
Mar 31, 2025
CM Management, LLC
250.00K
1.4%
+7.50K
+3.09%
Mar 31, 2025
View more
Related ETFs
Updated: Sat, Aug 2
Updated: Sat, Aug 2
Name
Proportion
iShares Genomics Immunology and Healthcare ETF
0.75%
Zacks Small/Mid Cap ETF
0.6%
ALPS Medical Breakthroughs ETF
0.23%
SPDR S&P Biotech ETF
0.09%
iShares Micro-Cap ETF
0.07%
Vanguard US Momentum Factor ETF
0.06%
Direxion Daily S&P Biotech Bull 3X Shares
0.05%
Vanguard US Multifactor ETF
0.05%
Franklin US Small Cap Multifactor Index ETF
0.04%
Principal U.S. Small-Cap ETF
0.04%
View more
iShares Genomics Immunology and Healthcare ETF
Proportion0.75%
Zacks Small/Mid Cap ETF
Proportion0.6%
ALPS Medical Breakthroughs ETF
Proportion0.23%
SPDR S&P Biotech ETF
Proportion0.09%
iShares Micro-Cap ETF
Proportion0.07%
Vanguard US Momentum Factor ETF
Proportion0.06%
Direxion Daily S&P Biotech Bull 3X Shares
Proportion0.05%
Vanguard US Multifactor ETF
Proportion0.05%
Franklin US Small Cap Multifactor Index ETF
Proportion0.04%
Principal U.S. Small-Cap ETF
Proportion0.04%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Jun 25, 2024
Merger
10<1
Jun 25, 2024
Merger
10<1
Jun 25, 2024
Merger
10<1
Jun 25, 2024
Merger
10<1
Date
Type
Ratio
Jun 25, 2024
Merger
10<1
Jun 25, 2024
Merger
10<1
Jun 25, 2024
Merger
10<1
Jun 25, 2024
Merger
10<1
